Telegram-канал fundamental3 - Fundamental Analysis (Long term): Unsorted

Fundamental Analysis (Long term)

22 Jul 2025 05:44

Blue Jet Healthcare Ltd. – Fundamental Investment Research

1. Company Snapshot

Business Description:
Blue Jet Healthcare Ltd. is a B2B pharmaceutical company specializing in the development, manufacture, and supply of contrast media intermediates (CMI), high-intensity sweeteners, and advanced pharmaceutical intermediates and APIs. Its CDMO (contract development and manufacturing organization) solutions cater globally to leading innovators in pharma imaging and specialty chemical segments.

Revenue Breakdown (Q4FY25/TTM):
- By Segment (FY25):
- Pharmaceutical Intermediates & APIs: Fastest growing, revenue up 4x YoY in Q4, now a major contributor[3].
- Contrast Media Intermediates: Stabilized after H1 dip, sees renewed validation and commercial sales; new launches in pipeline[3].
- High-Intensity Sweeteners: Marginal growth, focused on FMCG relationships, rationalized product portfolio.

- Geography (FY25):
- Europe: ~75–78% of revenue (mainly Norway, rest of Europe)
- India: ~12%
- Rest of World: 10–12%.

- Product Line (Q4FY25):
- CMI: 44.7% of revenue (9MFY25)
- Sweeteners: 11–12%
- Pharma Intermediates & APIs: Remainder; growing at the fastest pace.

Business Model:
Firmly B2B, with long-term supply agreements and strong presence in regulated and export markets. There is no significant B2C exposure.

Key Customers:
- CMI: GE Healthcare, Guerbet, Bracco Imaging (together >70% of global CMI market)
- Sweeteners: Colgate-Palmolive, Unilever, Prinova US LLC
- Pharma Intermediates/APIs: Olon S.p.A, Hovione Farmaciência, Esperion Therapeutics.

Manufacturing Footprint:
Four facilities in Maharashtra (Shahad, Ambernath Units 1 & 2, Mahad), with new capacity additions and greenfield site at Dahej (Gujarat) in planning.
Combined key capacity at Ambernath and Mahad supports flexible product switching and customer audits.

Distribution Reach:
Supply to more than 16 global customers across Europe, North America, South America, and Asia; strong compliance orientation.

Promoter Group & Ownership:
- Promoters (Arora family): 86%
- Institutions (FII/DII): ~3%
- Retail: ~11%
- No major group companies reported. Management led by Akshay B. Arora (Chairman) and Shiven Arora (MD).

2. Business Model and Industry-Specific Unit Economics

Revenue Model:
- Sales from CMI, sweeteners, and custom pharma intermediate manufacturing via take-or-pay contracts and multiyear agreements[3].
- Backward integration of key starting materials (KSM) for contrast media boosts margins and supply resilience.

Industry KPIs:
- Gross margin: ~54.9% in Q4FY25 (stable YoY, improved sequentially)
- EBITDA margin: 41.1% in Q4 (full-year 36.7%, up >400bps YoY)
- Capacity utilization: 75% overall (up to 65% in new PI lines)
- Customer concentration: Key. Top 3 CMI customers account for a major share.
- Working capital cycle: Cash conversion cycle at 139 days (Q4FY25), increased with growth but now steady
- Fixed cost leverage: Margin uptick driven by new capacity absorption and larger scale

Gross Margin Drivers:
- Operational efficiency (automation, process engineering)
- Premium specialty products (advanced intermediates for NCEs)
- Reduced raw material import dependency via backward integration